Journal article
Optimizing Survival and the Changing Landscape of Targeted Therapy for Intermediate and Advanced Hepatocellular Carcinoma: A Systematic Review
Abstract
BACKGROUND: Systemic therapy for hepatocellular carcinoma (HCC) consisting of the tyrosine kinase inhibitor sorafenib has remained unchanged for over a decade, although results from phase III targeted therapy trials have recently emerged. This review considers available phase III evidence on the use and sequencing of targeted therapy for intermediate and advanced non-locoregional therapy (LRT) eligible HCC and discusses implications for …
Authors
Lim H; Ramjeesingh R; Liu D; Tam VC; Knox JJ; Card PB; Meyers BM
Journal
Journal of the National Cancer Institute, Vol. 113, No. 2, pp. 123–136
Publisher
Oxford University Press (OUP)
Publication Date
February 1, 2021
DOI
10.1093/jnci/djaa119
ISSN
0027-8874
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AnilidesAntibodies, Monoclonal, HumanizedCarcinoma, HepatocellularClinical Trials, Phase III as TopicCombined Modality TherapyHumansImmune Checkpoint InhibitorsLiver NeoplasmsMolecular Targeted TherapyNeoplasm Recurrence, LocalPhenylurea CompoundsProtein Kinase InhibitorsPyridinesQuinolinesSorafenibSurvival AnalysisVascular Endothelial Growth Factor ARamucirumab